VIETNAM VACCINE COMPANY (VNVC)

VNVC is the most modern vaccination system in Vietnam, with the largest scale and level of investment nationwide, while actively participating in community-oriented activities. Since its establishment in 2017, VNVC has introduced more than 20 new and next-generation vaccines into Vietnam, contributing to an unprecedented increase in immunization coverage rates and expanding access to high-quality vaccines for the population.

Beyond vaccination services, VNVC is gradually expanding its role along the vaccine industry value chain through the VNVC Vaccine and Biological Manufacturing Plant project in Tây Ninh. The project is being developed in accordance with international standards, with a long-term orientation toward vaccine research, development, and manufacturing capacity, aligned with Resolution No. 57 of the Politburo on strengthening scientific and technological autonomy and enhancing Vietnam’s capacity for producing medical biological products.

EFFORTS TO TRANSFORM THE LANDSCAPE OF PRIVATE VACCINATION SERVICES IN VIETNAM

VNVC was established on 29 June 2017, with its first center launched in Hanoi at a time when Vietnam was experiencing severe shortages of many privately provided vaccines, particularly essential vaccines for children. At that time, many families were forced to wait in long queues for extended periods, or even take their children abroad for vaccination. The emergence of VNVC played a significant role in addressing these shortages, while introducing a modern, civilized, and more accessible vaccination model for millions of people.

From a single initial center, after more than eight years of development, VNVC has grown into a nationwide system of more than 250 vaccination centers, forming the largest private vaccination network in Vietnam. Each center is systematically invested in with modern infrastructure, standardized vaccination safety procedures, and professional customer care services, contributing to the elevation of preventive healthcare standards and meeting the growing immunization needs of the community.

Alongside the expansion of its center network, VNVC has built one of Vietnam’s most advanced professional operating platforms, comprising hundreds of cold storage facilities, GSP-compliant cold chain systems, storage capacity for tens of millions of vaccine doses, fleets of specialized refrigerated vehicles, and 24/7 automated temperature monitoring. On this modern infrastructure foundation, a workforce of more than 11,000 doctors, nurses, and healthcare personnel, professionally trained in vaccination safety, rapid response to adverse reactions, and customer care, has enabled VNVC to safely administer tens of millions of vaccine doses, making it a trusted destination for millions of families nationwide.

As an international vaccine bridge, VNVC has established strategic partnerships with leading global pharmaceutical and vaccine corporations such as Pfizer, GSK, Sanofi, MSD, Takeda, Abbott, and AstraZeneca. Through these collaborations, VNVC has introduced nearly 20 new and next-generation vaccines to Vietnam for the first time, including vaccines for dengue fever, next-generation pneumococcal disease, next-generation meningococcal disease, RSV vaccines and monoclonal antibodies, and shingles vaccines, while maintaining a stable supply of nearly 50 other essential vaccines. These efforts have enabled people in Vietnam to access advanced vaccines almost on par with developed countries, contributing to an unprecedented increase in national immunization coverage.

In parallel with its professional activities, VNVC consistently implements large-scale, wide-reaching free vaccination programs for the community, targeting disadvantaged children, older adults, pregnant women, veterans, and residents of remote and underserved areas. Many programs are conducted continuously nationwide, such as tetanus vaccination for pregnant women, immunization for children in extremely disadvantaged regions, and support for influenza and pneumococcal vaccination for older adults and high-risk groups. These initiatives demonstrate VNVC’s commitment to ensuring equitable access to vaccines for all members of society.

DEVELOPMENT OF THE VNVC VACCINE AND BIOLOGICAL MANUFACTURING PLANT

Building on its achievements in vaccination services, preventive medicine, and international cooperation, in 2025 VNVC entered a new phase of development with the groundbreaking of the VNVC Vaccine and Biological Manufacturing Plant in Long An Province. This is a strategically significant project implemented in the context of Vietnam’s execution of Politburo Resolution No. 57 on strengthening scientific and technological autonomy, proactively securing vaccine supply sources, and enhancing national health security capacity.

The groundbreaking ceremony of the VNVC Vaccine and Biological Manufacturing Plant took place at a special event attended by French President Emmanuel Macron, marking an important milestone in VNVC’s development strategy and affirming the position, credibility, and international cooperation capacity of a Vietnamese enterprise in the field of preventive healthcare.

The plant is being constructed on an area of more than 26,000 m² within Phu An Thanh Industrial Park, with an initial total investment of approximately VND 2,000 billion. The design is undertaken by Rieckermann Group (Germany), an organization with more than 130 years of experience in pharmaceutical and biologics plant design. Aiming for global standards, the facility applies the most stringent regulations, including EU GMP, FDA GMP, and WHO GMP, while also meeting international GLP and AAALAC standards for animal research areas, ensuring high requirements for safety, scientific ethics, environmental protection, and operational technology under a “green factory – smart factory” model.

Upon completion, the plant will have a capacity of up to 100 million vaccine doses per year, with three modern filling and packaging lines, including advanced isolator technology and Southeast Asia’s first prefilled syringe filling line, meeting strict international requirements for sterility, safety, and quality. From late 2027, the plant is expected to begin receiving technology transfer from Sanofi (France), gradually localizing the production of important vaccines and new-technology vaccines to serve domestic demand at reasonable costs and participate in the global vaccine supply chain. Vaccines with high demand and significant public health impact will be prioritized in the initial production phase.

Currently, the VNVC Vaccine and Biological Manufacturing Plant has signed cooperation and technology transfer agreements with major partners such as Sanofi (France), Pfizer (USA), GSK (UK), RDIF, and Medsintez (Russia). With a strategy focused on attracting high-quality scientific and technological human resources in the vaccine and biomedical fields, VNVC aims to gradually master advanced vaccine manufacturing technologies, including mRNA technology for cancer treatment and other biomedical applications. This represents an important step toward achieving vaccine self-reliance under Politburo Resolution No. 57, strengthening national health security, and elevating Vietnam’s position on the regional and global vaccine industry map.

Vietnam Vaccine Joint Stock Company (VNVC) and Pfizer Vietnam (a subsidiary of Pfizer, USA) have signed a strategic partnership to share vaccine manufacturing expertise for the VNVC Vaccine and Biologicals Manufacturing Plant.
Vietnam Vaccine Joint Stock Company (VNVC) and GSK Vietnam (a subsidiary of GSK, United Kingdom) have formalized an enhanced strategic partnership focused on expanding access to new medicines and vaccines, advancing scientific research, and strengthening collaboration in vaccine manufacturing.
VNVC and Sanofi have signed a cooperation agreement on vaccine manufacturing technology transfer for the VNVC Vaccine and Biologicals Manufacturing Plant.
Vietnam Vaccine Joint Stock Company (VNVC) and the Russian Direct Investment Fund (RDIF) have signed a strategic cooperation agreement in scientific research, vaccine technology transfer, and the development of advanced biological products.
In October 2025 in Ho Chi Minh City, with the attendance of Will Lawrenson, Deputy British Consul General in Ho Chi Minh City, Vietnam Vaccine Joint Stock Company (VNVC), Tam Anh General Hospital System, and GSK Vietnam held a high-level working session and signed a memorandum of understanding to expand access to new medicines and vaccines, promote clinical research, and strengthen knowledge exchange in vaccine manufacturing.
The VNVC Vaccine and Biologicals Manufacturing Plant and Medsintez (Russia) have signed a cooperation agreement on the transfer of advanced biopharmaceutical manufacturing technologies.

Alongside the production area, VNVC is investing in a 1,500 m² Research and Development (R&D) Center focused on research, improvement, and application of advanced vaccine technologies, particularly mRNA platforms and next-generation biotechnologies. The center aims to cooperate with universities, research institutes, and global pharmaceutical corporations to conduct preclinical and clinical studies directly in Vietnam, shortening technology access timelines and accelerating regulatory approval processes to bring high-quality products to the public as early as possible.

With a long-term vision, a structured development strategy, and a pioneering spirit at every stage, VNVC is gradually building a comprehensive preventive healthcare ecosystem for Vietnam, from vaccination services and international cooperation to research, manufacturing, and proactive vaccine supply. Throughout its formation and development, VNVC has not only contributed to increasing vaccination coverage and protecting millions of people each year, but has also played an increasingly important role in Vietnam’s national health security strategy. The implementation of the VNVC Vaccine and Biological Manufacturing Plant in Long An marks a new milestone, enabling Vietnamese enterprises to participate more deeply in the global value chain of the vaccine industry, while realizing the aspiration for technological autonomy, manufacturing self-reliance, and equitable access to advanced vaccines at reasonable costs for all Vietnamese children and adults.